William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s ...

Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2–Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry The ...

Researchers have developed a system for designing protein inhibitors with reversible activity. The method is based on a supramolecular drug that results from the interaction of two or more molecules ...